Interest in Extended Release Naltrexone among Opioid Users

Publisher： Karger

E-ISSN： 1421-9891|22|6|301-305

ISSN： 1022-6877

Source： European Addiction Research, Vol.22, Iss.6, 2016-07, pp. : 301-305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intranasal administration of crushed ALO‐02 (extended‐release oxycodone with sequestered naltrexone): A randomized, controlled abuse‐potential study in nondependent recreational opioid users

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1351-1361

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mortality in opioid users given oral naltrexone

By  

DRUG AND ALCOHOL REVIEW, Vol. 34, Iss. 1, 2015-01 ,pp. : 90-96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Extended Release Naltrexone for Alcohol Use Disorders: Quasi‐Experimental Effects on Mortality and Subsequent Detoxification Episodes

By  

ALCOHOLISM (ELECTRONIC), Vol. 39, Iss. 1, 2015-01 ,pp. : 79-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Naltrexone/bupropion prolonged release

By  

PRACTICAL DIABETES (INCORPORATING CARDIABETES), Vol. 32, Iss. 3, 2015-04 ,pp. : 114-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids

By Mercadante Sebastiano  

Current Medical Research and Opinion, Vol. 29, Iss. 6, 2013-06 ,pp. : 661-666

Informa Healthcare

Access to resources Recommend Favorite